Actinium Pharmaceuticals, Inc. reported results from the Phase 3 SIERRA trial of Iomab-B. The company said Iomab-B achieved the primary endpoint in the SIERRA trial of durable Complete Remission or dCR of at least 6 months with high statistical significance, with 22% of patients randomized to the Iomab-B arm achieving dCR and 0% of patients in the control arm achieving dCR, irrespective of TP53 mutational status.